The making of bispecific antibodies
During the past two decades we have seen a phenomenal evolution of bispecific antibodies
for therapeutic applications. The 'zoo'of bispecific antibodies is populated by many different …
for therapeutic applications. The 'zoo'of bispecific antibodies is populated by many different …
[HTML][HTML] A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …
[HTML][HTML] Alternative molecular formats and therapeutic applications for bispecific antibodies
C Spiess, Q Zhai, PJ Carter - Molecular immunology, 2015 - Elsevier
Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a
century after they were first described. Two bispecific antibodies, catumaxomab (Removab® …
century after they were first described. Two bispecific antibodies, catumaxomab (Removab® …
David vs. Goliath: the structure, function, and clinical prospects of antibody fragments
A Bates, CA Power - Antibodies, 2019 - mdpi.com
Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies
have become the largest class of biopharmaceuticals with over 80 antibodies currently …
have become the largest class of biopharmaceuticals with over 80 antibodies currently …
Bispecific antibodies and their applications
G Fan, Z Wang, M Hao, J Li - Journal of hematology & oncology, 2015 - Springer
Bispecific antibodies (BsAbs) recognize two different epitopes. This dual specificity opens up
a wide range of applications, including redirecting T cells to tumor cells, blocking two …
a wide range of applications, including redirecting T cells to tumor cells, blocking two …
[HTML][HTML] Bispecific antibodies
Bispecific antibodies (bsAbs) combine specificities of two antibodies and simultaneously
address different antigens or epitopes. BsAbs with 'two-target'functionality can interfere with …
address different antigens or epitopes. BsAbs with 'two-target'functionality can interfere with …
Emerging strategies for develo** next-generation protein therapeutics for cancer treatment
JR Kintzing, MVF Interrante, JR Cochran - Trends in pharmacological …, 2016 - cell.com
Protein-based therapeutics have been revolutionizing the oncology space since they first
appeared in the clinic two decades ago. Unlike traditional small-molecule …
appeared in the clinic two decades ago. Unlike traditional small-molecule …
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
C Klein, C Sustmann, M Thomas, K Stubenrauch… - MAbs, 2012 - Taylor & Francis
The development of bispecific antibodies has attracted substantial interest, and many
different formats have been described. Those specifically containing an Fc part are mostly …
different formats have been described. Those specifically containing an Fc part are mostly …
Unraveling the macromolecular pathways of IgG oligomerization and complement activation on antigenic surfaces
IgG antibodies play a central role in protection against pathogens by their ability to alert and
activate the innate immune system. Here, we show that IgGs assemble into oligomers on …
activate the innate immune system. Here, we show that IgGs assemble into oligomers on …
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
X Guo, Y Wu, Y Xue, N **e, G Shen - Frontiers in Immunology, 2023 - frontiersin.org
Recent progressions in immunotherapy have transformed cancer treatment, providing a
promising strategy that activates the immune system of the patient to find and eliminate …
promising strategy that activates the immune system of the patient to find and eliminate …